Key result
CMR T2-mapping and 18FDG PET-CT synergistically identify active cardiac sarcoidosis and monitor treatment response.
Why the study?
The review aimed to synthesize current knowledge regarding imaging of inflammation in cardiac sarcoidosis to aid in differentiating active from chronic, silent disease.
What is the role of CMR and 18FDG-PET-CT in diagnosing and monitoring inflammation in cardiac sarcoidosis?
Systematic Review
What is the role of CMR and 18FDG-PET-CT in diagnosing and monitoring inflammation in cardiac sarcoidosis?
The hybrid application of CMR and 18F-FDG PET-CT has evolved as the standard procedure for detecting active inflammation and monitoring therapeutic response in cardiac sarcoidosis.
No takes yet. Share an insight, caveat, or question.
Supports hybrid CMR-PET protocols as standard for cardiac sarcoidosis; systematic review strengthens evidence for synergistic detection and monitoring.
Treiber et al. (2024) conducted a systematic review in Cardiac sarcoidosis. Cardiac magnetic resonance (CMR) and 18FDG PET-CT was evaluated. Cardiac magnetic resonance T2-mapping and 18FDG PET-CT scans synergistically identify active cardiac sarcoidosis and reliably monitor therapeutic response.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: